A comprehensive market report projects the global biologics API market will reach $101.84 billion by 2030, growing at a CAGR of 8.8%. The market, valued at approximately $65.4 billion in 2025, is propelled by advances in cell and gene therapies, rising demand for personalized biologics, and expanding commercial-scale production.
The cell and gene therapy market is projected to reach approximately $40 billion by 2030, creating demand for specialized API manufacturing including viral vector production and aseptic fill-finish. Biosimilar pipelines continue expanding, with over $300 billion in projected biologics loss-of-exclusivity revenue over the next decade. Amneal's recent $1.1 billion acquisition of Kashiv BioSciences underscores the urgency of building end-to-end biosimilar platforms.
Government support is accelerating growth. The FDA PreCheck pilot program reshapes domestic manufacturing, while agencies in China, India, and South Korea implement policies to attract biologics CDMO investments.
The biologics CDMO market itself is projected to reach $48.07 billion by 2030. Small and mid-sized biotechs representing roughly 70 percent of novel candidates often lack manufacturing infrastructure, making outsourcing essential. Automation, single-use bioreactor technology, and continuous bioprocessing are driving competitive advantage among leading CDMOs.
Traditional small-molecule API manufacturers must evaluate whether to invest in biologics capabilities. Key considerations include analytical capabilities for biologics quality control, regulatory expertise for submissions across major markets, cold-chain logistics infrastructure, and CDMO partnerships for integrated supply solutions.
North America leads in biologics innovation, but Asia-Pacific is rapidly building capacity. South Korea biopharma exports hit a $2 billion record in early 2026. China expands biologics manufacturing under favorable policies, while Indian API manufacturers increasingly invest in biologics capabilities.
Suppliers who invest now in capabilities, partnerships, and infrastructure for biologics will be well-positioned to capture value as the industry transitions toward large-molecule therapeutics.
